MKI67 and neoplasm: The biomarkers that are currently in use to stratify patients for local treatment are tumour grade and Ki-67 index Novel biomarkers in patients who are eligible for local treatment may enable prospective clinical trials to identify the patients that benefit most from local treatment of NETLM.